Search research articles
Contact Us
Filters
Showing results (111-120 of 135) with videos related to
Page
of 14
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN
|
August 11, 2010
Modification and implementation of NCCN guidelines on lymphomas in the Middle East and North Africa region
Ali Bazarbachi, Hamdy A Azim, Hussain Alizadeh, et al.
Archives of Medical Science : AMS
|
August 2, 2021
Effectiveness of bendamustine in relapsed or refractory lymphoma cases: a Turkish Oncology Group study
Nuri Karadurmus, Semra Paydas, Ece Esin, et al.
Oncology
|
June 28, 2023
Comparison of the Efficacy and Safety of 3 Months of CAPOX Followed by 3 Months of Capecitabine and 6 Months of CAPOX/FOLFOX in the Adjuvant Treatment of Low-Risk Stage III Colon Cancer Treated Surgically
Murat Bardakci, Derya Demirtas Esmer, Emre Hafizoglu, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 3, 2020
Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma
Meral Beksac, Yildiz Aydin, Hakan Goker, et al.
Current Medical Research and Opinion
|
May 29, 2024
Evaluation of the efficacy and safety of nivolumab in the second- or later-line treatment of patients with locally advanced/metastatic non-small cell lung cancer in Türkiye: a retrospective multicenter non-interventional registry study
Nuri Karadurmus, Muhammet Ali Kaplan, Mehmet Ali Nahit Sendur, et al.
Lancet (London, England)
|
February 14, 2021
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
Ahmet Sezer, Saadettin Kilickap, Mahmut Gümüş, et al.
Journal of Cancer Research and Therapeutics
|
December 17, 2021
Merkel cell carcinoma in Turkey: A multicentric study
Fatih Yildiz, Umut Demirci, Ahmet Küçükarda, et al.
American Journal of Cancer Research
|
February 9, 2026
Second-line nab-paclitaxel and gemcitabine for advanced pancreatic cancer following FOLFIRINOX: outcomes and insights
Aysegul Merc Cetınkaya, Ali Murat Tatlı, Sabin Goktas Aydın, et al.
Cancer Investigation
|
December 13, 2021
Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study
Ahmet Bilici, Mukremin Uysal, Serkan Menekse, et al.
Balkan Medical Journal
|
January 24, 2020
Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial
Atakan Demir, Nil Molinas Mandel, Semra Paydas, et al.
Page
of 14
Search research articles
Search
Showing results (111-120 of 135) with videos related to
Sort By:
Page
of 14
Journal of the National Comprehensive Cancer Network : JNCCN
|
August 11, 2010
Modification and implementation of NCCN guidelines on lymphomas in the Middle East and North Africa region
Ali Bazarbachi, Hamdy A Azim, Hussain Alizadeh, et al.
Archives of Medical Science : AMS
|
August 2, 2021
Effectiveness of bendamustine in relapsed or refractory lymphoma cases: a Turkish Oncology Group study
Nuri Karadurmus, Semra Paydas, Ece Esin, et al.
Oncology
|
June 28, 2023
Comparison of the Efficacy and Safety of 3 Months of CAPOX Followed by 3 Months of Capecitabine and 6 Months of CAPOX/FOLFOX in the Adjuvant Treatment of Low-Risk Stage III Colon Cancer Treated Surgically
Murat Bardakci, Derya Demirtas Esmer, Emre Hafizoglu, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 3, 2020
Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma
Meral Beksac, Yildiz Aydin, Hakan Goker, et al.
Current Medical Research and Opinion
|
May 29, 2024
Evaluation of the efficacy and safety of nivolumab in the second- or later-line treatment of patients with locally advanced/metastatic non-small cell lung cancer in Türkiye: a retrospective multicenter non-interventional registry study
Nuri Karadurmus, Muhammet Ali Kaplan, Mehmet Ali Nahit Sendur, et al.
Lancet (London, England)
|
February 14, 2021
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
Ahmet Sezer, Saadettin Kilickap, Mahmut Gümüş, et al.
Journal of Cancer Research and Therapeutics
|
December 17, 2021
Merkel cell carcinoma in Turkey: A multicentric study
Fatih Yildiz, Umut Demirci, Ahmet Küçükarda, et al.
American Journal of Cancer Research
|
February 9, 2026
Second-line nab-paclitaxel and gemcitabine for advanced pancreatic cancer following FOLFIRINOX: outcomes and insights
Aysegul Merc Cetınkaya, Ali Murat Tatlı, Sabin Goktas Aydın, et al.
Cancer Investigation
|
December 13, 2021
Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study
Ahmet Bilici, Mukremin Uysal, Serkan Menekse, et al.
Balkan Medical Journal
|
January 24, 2020
Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial
Atakan Demir, Nil Molinas Mandel, Semra Paydas, et al.
Page
of 14